Fluorescence anisotropy assays to characterize the binding of aptamers to their protein targets can be made more efficient without loss of precision through the use of high-efficiency, low-volume plates.
The biomarker CA125, a peptide epitope located in several tandem repeats of the mucin MUC16, is the gold standard for monitoring regression and recurrence of high-grade serous ovarian cancer in response to therapy. However, the CA125 epitope along with several structural features of the MUC16 molecule are ill defined. One central aspect still unresolved is the number of tandem repeats in MUC16 and how many of these repeats contain the CA125 epitope. Studies from the early 2000s assembled short DNA reads to estimate that MUC16 contained 63 repeats. Here, we conduct Nanopore long-read sequencing of MUC16 transcripts from three primary ovarian tumors and established cell lines (OVCAR3, OVCAR5, and Kuramochi) for a more exhaustive and accurate estimation and sequencing of the MUC16 tandem repeats. The consensus sequence derived from these six sources was confirmed by proteomics validation and agrees with recent additions to the NCBI database. We propose a model of MUC16 containing 19—not 63—tandem repeats. In addition, we predict the structure of the tandem repeat domain using the deep learning algorithm, AlphaFold. The predicted structure displays an SEA domain and unstructured linker region rich in proline, serine, and threonine residues in all 19 tandem repeats. These studies now pave the way for a detailed characterization of the CA125 epitope. Sequencing and modeling of the MUC16 tandem repeats along with their glycoproteomic characterization, currently underway in our laboratories, will help identify novel epitopes in the MUC16 molecule that improve on the sensitivity and clinical utility of the current CA125 assay. Significance: Despite its crucial role in clinical management of ovarian cancer, the exact molecular sequence and structure of the biomarker, CA125, are not defined. Here, we combine long-read sequencing, mass spectrometry, and in silico modeling to provide the foundational dataset for a more complete characterization of the CA125 epitope.
Reversed-phase liquid chromatography (RPLC) is widely used to reduce sample complexity prior to mass spectrometry (MS) analysis in bottom-up proteomics. Improving peptide separation in complex samples enables lower-abundance proteins to be identified. Multidimensional separations that combine orthogonal separation modes improve protein and peptide identifications over RPLC alone. Here we report a preparative capillary electrophoresis (CE) fractionation method that combines CE and RPLC separations. Using this method, we demonstrate improved protein and peptide identification in a tryptic digest of E. coli cell lysate, with 132 ± 33% more protein identifications and 185 ± 65% more peptide identifications over non-fractionated samples. Fractionation enables detection of lower-abundance proteins in this complex sample. We demonstrate improved coverage of ovarian cancer biomarker MUC16 isolated from conditioned cell media, with 6.73% sequence coverage using CE fractionation compared to 2.74% coverage without preparative fractionation. This new method will allow researchers performing bottom-up proteomics to harness the advantages of CE separations while using widely available LC-MS/MS instrumentation.
Hsp90 is a central molecular chaperone responsible for the folding and activation of >400 client proteins, causing it to be a highly sought after drug target for the treatment of cancer. Hsp90 pan-inhibitors have been evaluated in the clinic, but on- and off-target toxicities have limited their development. The emergence of Hsp90β-selective inhibitors has been proposed as a safer therapeutic alternative. However, since they in theory only target a portion of the Hsp90-regulated proteome, a deeper understanding of their mechanism of action and whether they exhibit selectivity for cancer over normal cells has remained uninvestigated. Herein we show that Hsp90β-selective inhibitors NDNB1 and NDNB1182 exhibit a moderate selectivity for TNBC over normalized MCF-10A cells in contrast to pan-inhibitors which do not exhibit a selectivity. This manuscript contains the first proteomic analysis of Hsp90β-selective inhibitors. We have employed a traditional bottom-up LC-MS/MS proteomics approach to explore the potential mechanisms of action underlying the anti-cancer effects of NDNB1 and NDNB1182 against triple-negative breast cancer (TNBC). Primarily, inhibition of kinases and associated cell signaling pathways, cell cycle proteins, and DNA repair were notable processes affected by Hsp90β inhibition, to name a few. Further investigation of the impact on Hsp90β interactors allowed a fuller understanding of Hsp90β-dependent processes. We also identified RAD9A, CDK1, and RPS9 as potential Hsp90β client substrates. The three example proteins selected exemplify a mechanistic explanation for inhibition of DNA-repair (RAD9A), cell cycle (CDK1), and translation (RPS9), shedding some light on some of the implications of Hsp90β inhibition as it pertains to TNBC. Therefore, previously unknown clients, Hsp90β interactors, or Hsp90β-regulated proteins could be determined using the results from this study.
11 April 2024 in Microbiology Resource Announcements
N-terminal acetylation in Mycobacterium tuberculosis is correlated with pathogenic activity. We used genomics and bottom-up proteomics to identify protein Emp1 as the sole acetyltransferase responsible for acetylation of EsxA, a known virulence factor. Using custom data analysis, we screened the proteome to identify 22 additional putative substrates of Emp1.